Evofem Biosciences (EVFM) 10-Q2022 Q1 Quarterly report

Filed: 10 May 22, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accomplish, alleging, answered, antagonist, arrangement, bacterial, Canada, capped, captioned, case, chronic, clarify, compatibility, confirmatory, counterclaim, counterclaimed, Court, created, damage, deemed, denied, detail, detailed, dispute, District, diversity, ectopic, EMA, EVFM, evidence, FASB, fee, Florida, forfeit, forward, fractional, freestanding, frequently, geopolitical, goal, Hedging, highest, highlighted, HIV, host, importantly, impossible, infertility, inflammatory, inflation, infringement, insufficient, la, LLC, long, lose, lowest, margin, meaningful, Mexican, modification, motion, MPT, negotiating, Orion, pain, para, patch, path, pelvic, permanent, philanthropic, PID, pregnant, premium, priority, proceed, propelled, proportionate, purpose, PWERM, ratio, rebound, redeem, redeemable, reset, retrospective, retrospectively, revealed, ring, ROU, sensitive, shipped, side, single, Southern, stability, strong, Subordinated, Subtopic, symbol, TherapeuticsMD, threshold, Topic, treble, turmoil, Ukraine, unaware, uptick, vigorously, voting

Removed: academic, acting, added, AMPOWER, announced, approve, assumption, authorized, began, behavior, birth, bona, Book, borrowing, cancer, category, cautioned, climbed, Code, Committee, commonly, community, composition, consistent, constant, consulting, contingent, copper, corrective, covering, critical, deployment, developed, device, director, Dispensing, Distinguishing, divided, educational, employment, entering, Equivalence, established, Evergreen, excluding, execute, expedient, expired, fact, female, fide, fighting, Flex, formulation, free, guide, higher, hire, implanted, importance, individually, inflammation, intention, introduction, invest, IUD, living, Lynch, Marketplace, mechanism, midpoint, nationally, nationwide, newly, noncancelable, observed, oncology, Orange, owner, participant, passing, Piper, pivotal, practical, present, preservation, Preventive, promoting, publicly, qualify, quality, ratably, Rating, reclassification, recommended, recovering, Regulation, requisite, revise, Sandler, satisfy, smaller, space, standing, starkly, steered, step, STI, sublease, surrendered, Therapeutic, turn, undergoing, unique, USPTO, vest, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated EVFM transcripts

EVFM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Evofem Biosciences, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), each of the undersigned officers of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of such officer’s knowledge:


			(1)			The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


			(2)			The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 10, 2022	By:	/s/ Saundra Pelletier
		Saundra Pelletier
		President, Chief Executive Officer, and Interim Chairperson of the Board
		(Principal Executive Officer)


Date: May 10, 2022	By:	/s/ Justin J. File
		Justin J. File
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Evofem Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.